← Therapeutics
Details checkedClinical trial listing onlyCheckedregistry
Aspirin cisplatin-ototoxicity prevention study
Also known as: Aspirin, ASA cisplatin ototoxicity study
Institution-led study
Sponsor / Institution
Institution-led study
Program Type
Therapeutic
Modality
Small Molecule
Stage
Not applicable
Status
Unknown
Target Gene
—
Route / Mode
Oral
Confidence
84%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
Canada
Population
adult, cisplatin-ototoxicity
Trial IDs
1
Mechanism
Randomized quadruple-masked study evaluating low-dose aspirin during cisplatin chemotherapy to test prevention of cisplatin-induced ototoxicity.
Indications
Notes
Registry-verified hospital-led otoprotection study. The registry status is unknown and this should not be displayed as a current company-sponsored hearing drug program.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, company, allCompanies, isIndustrySponsored, programType, modality, mechanism, indications...
IDs: NCT00578760
Key Events
Clinical Trials (1)
Data Checks
institution-led-studyregistry-only-evidencecurrent-status-unknown-in-registrynot-confirmed-current-product
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2